HTG Molecular Diagnostics, Inc. (HTGMQ)
Market Cap | 3.32K |
Revenue (ttm) | 3.47M |
Net Income (ttm) | -9.75M |
Shares Out | 2.21M |
EPS (ttm) | -4.40 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1 |
Open | 0.0015 |
Previous Close | 0.0015 |
Day's Range | 0.0015 - 0.0015 |
52-Week Range | 0.0010 - 0.6000 |
Beta | 2.70 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About HTGMQ
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company dist... [Read more]
Financial Performance
In 2022, HTGMQ's revenue was $6.37 million, a decrease of -28.52% compared to the previous year's $8.91 million. Losses were -$21.59 million, 26.0% more than in 2021.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/y/g/press1-1897004.jpg)
HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention
TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its managemen...
![](https://cdn.snapi.dev/images/v1/m/z/press13-1892198.jpg)
HTG Highlights the Advantages of Its Drug Discovery Engine
TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of anot...
![](https://cdn.snapi.dev/images/v1/y/y/press5-1883845.jpg)
HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights
TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results f...
![](https://cdn.snapi.dev/images/v1/m/h/press18-1828101.jpg)
HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19
TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced there will be at...
![](https://cdn.snapi.dev/images/v1/a/b/press18-1700395.jpg)
HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event
TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/3/2/press19-1698208.jpg)
HTG Announces Certain Preliminary 2022 Unaudited Financial Results
Preliminary full year 2022 unaudited revenue of $6.4 million
![](https://cdn.snapi.dev/images/v1/1/1/conf18-1688797.jpg)
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/h/u/press11-1686787.jpg)
HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering
TUCSON, Ariz., Dec. 23, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/n/7/press7-1684074.jpg)
HTG Molecular Diagnostics Announces Pricing of a $10 Million Public Offering
TUCSON, Ariz., Dec. 21, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/d/m/press9-1682832.jpg)
HTG Announces One-for-Twelve Reverse Stock Split
TUCSON, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/y/e/conf7-1669475.jpg)
HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/c/t/press15-1663970.jpg)
HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences
TUCSON, Ariz., Dec. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/u/5/press2-1631352.jpg)
HTG Molecular Diagnostics Reports Third Quarter 2022 Results
TUCSON, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/6/n/press9-1599641.jpg)
HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications
TUCSON, Ariz. and PARIS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptom...
![](https://cdn.snapi.dev/images/v1/0/y/press6-1580158.jpg)
HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., Oct. 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/w/c/press9-1557538.jpg)
HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide p...
![](https://cdn.snapi.dev/images/v1/y/0/press11-1551723.jpg)
The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test
TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pr...
![](https://cdn.snapi.dev/images/v1/p/2/conf6-1487124.jpg)
HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/u/u/press14-1457738.jpg)
HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/n/w/press15-1455909.jpg)
HTG Molecular Diagnostics Announces Amendment to Senior Loan Facility
TUCSON, Ariz., July 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/l/f/press5-1441338.jpg)
HTG Releases Second Whitepaper for its Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/x/j/press4-1434021.jpg)
Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer
TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/2/z/press17-1408942.jpg)
HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials
TUCSON, Ariz., June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/q/v/press12-1405078.jpg)
HTG Technology Featured in Multiple Scientific Abstracts Highlighting Novel Applications in Precision Medicine at ASCO 2022
TUCSON, Ariz., June 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide pro...
![](https://cdn.snapi.dev/images/v1/l/n/conf1-1379127.jpg)
HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference
TUCSON, Ariz., May 17, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide prof...